VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT

This study tests a combination treatment called VMAC (a multi-drug regimen) together with donor lymphocyte infusion (DLI) — a procedure that infuses immune cells from the original stem cell donor — in patients with acute myeloid leukemia (AML) who have relapsed after a stem cell transplant from a donor. **You may be eligible if...** - You are between 18 and 65 years old with confirmed AML that has relapsed after an allogeneic (donor) stem cell transplant - Your bone marrow shows 5% or more blast cells (a sign of relapse) - You are in reasonable health (ECOG 0–2) **You may NOT be eligible if...** - You have had a second transplant - You have had another cancer treated within the past 3 years - You have HIV, active hepatitis B or C, or active syphilis - You are pregnant or cannot use contraception during treatment - You have active serious heart disease (heart failure, low heart function, recent heart attack, or severe arrhythmia) - You have a mental illness that prevents cooperation with treatment Talk to your doctor to see if this trial is right for you.